Dr. Regan invented the automated pathogen detection system that LexaGene is currently developing. He comes to LexaGene from Bio-Rad Laboratories, where he managed a team of scientists developing tests for detecting pathogens, cancer, and neurological disorders using droplet digital PCR. Prior to Bio-Rad, Jack helped QuantaLife, a startup company, bring its product from concept to commercialization. He has also worked on automated sample preparation at Applied Biosystems/Life Technologies and did his post-doctoral training at Lawrence Livermore National Laboratory, where he developed automated instruments to detect respiratory pathogens and bio-threat agents. His doctoral training at the University of California San Francisco focused on influenza viral replication.
Mr. Rebeck has over 15 years of capital market experience and an established international financial network. Mr. Rebeck was a Vice President and Senior Investment Advisor with Canada’s largest independent investment bank, Canaccord Genuity, where he was responsible for raising significant risk capital for growth companies, with a particular focus on natural resources and medical technology. Daryl has since worked to provide management expertise and grow shareholder value for organizations he has worked with. He served as Senior VP of Corporate Finance of TSX listed Auryn Resources, a $250 million market cap mining exploration company. Previous to this Mr. Rebeck was a consultant of corporate finance with Cayden Resources Inc., which was sold to Agnico Eagle Mining Limited for $205 million in November 2014.
Mr. Slezak is a computer scientist who has been supporting biological research at Lawrence Livermore National Laboratory (LLNL) since 1978. Tom is currently the Associate Program Leader for Informatics at LLNL. In 2012, he was the first member of the Computations Directorate to be named a Distinguished Member of the Technical Staff. He was part of the Human Genome Program for 14 years, and was a developer of nation-wide BioWatch system. Tom has chaired major NIAID sequencing center and infectious disease center proposal reviews and has served on three National Academy panels on biodefense topics and for 3 years on the NAS DoD Standing Committee on Biodefense programs. Tom also co-chaired a Blue Ribbon Panel on bioinformatics for the CDC in 2011 that resulted in subsequent major new funding for Advanced Molecular Diagnostics and bioinformatics. Tom has run a Pathogen Bioinformatics team at LLNL since 2000 that has developed PCR assays, pan-microbial microarrays, and DNA sequence analysis software to support a broad range of pathogen detection and forensic programs in biodefense and human/animal health. Software developed by the team is in regular use world-wide.
Dr. Furtado has worked in the life sciences industry for over 30 years, with experience in discovery research, clinical diagnostic testing, product development and commercialization, M&A activity, fundraising and strategy. He currently serves as President and Founder of Biology for Global Good LLC and Chief Scientific Officer and Chief Regulatory Officer at Apton Biosystems. Additionally, as the former Vice President of R&D at Applied Biosystems, Dr. Furtado helped to build the company’s molecular diagnostics, genomic assays, human identification, food pathogen detection, animal health, pharmaceutical analytics, environmental testing and molecular medicine platforms, which generated over $500 million in revenue. Dr. Furtado has also served as a business development consultant to Bio-Rad, Advanced Cell Diagnostics, DxNow, RxFulcrum, Sample 6, Apton Biosystems and Vibrant Biosciences. He was Senior Director for Regulatory Affairs at Cepheid and appointed to the National Biodefense Science Board by the former Department of Health and Human Services Secretary Kathleen Sebelius.
Mr. Caruso has thirty years of broad executive management experience as a CEO and board member, contributing operational, financial, administrative, and general management leadership to public and private companies. He was one of the founding members of the management team of Palomar Medical Technologies, which developed many first-of-its-kind technologies including the first FDA OTC cleared laser for home use. As its CEO and Chairman of the Board of Directors, Mr. Caruso was instrumental in taking Palomar public in 1992, growing the company from a start up to its sale in 2013 for approximately $300M. Mr. Caruso was actively involved in the design and development of a number of the medical devices launched by Palomar and worked closely with many world-renowned research institutions such as Massachusetts General Hospital. Mr. Caruso has negotiated dozens of acquisitions, license agreements and joint development agreements in his career including with companies such as Johnson and Johnson and Gillette (now part of Proctor and Gamble Company).